Medios AG (MEDOF) Stock
Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through three segments: Patient-Specific Therapies; International Business; and Pharmaceutical Supply.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Peer Comparison
About Medios AG
Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through three segments: Patient-Specific Therapies; International Business; and Pharmaceutical Supply. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies. This segment also includes cytostatic preparations, antibody therapies, and parenteral nutrition solutions. The International Business International covers all activities in the international environment from the procurement of Active Pharmaceutical Ingredients, the sterile and non-sterile drugs and the supply of public and hospital pharmacies through homecare service. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases. Medios AG is founded in 2015 and was headquartered in Berlin, Germany.
Medios AG is headquartered in DE.
Medios AG (MEDOF) stock trades at $50.00 with a market capitalization of $1.28B. The stock is valued at a price-to-earnings (P/E) ratio of 20.15, price-to-book of 0.52, price-to-sales of 0.13. Over the past 52 weeks the stock has ranged between $13.64 and $50.00, and currently trades at its 52-week high.
On profitability, Medios AG generates a return on equity (ROE) of 2.69%, return on capital employed of 5.99%, an operating margin of 2.06%, a net profit margin of 0.66%.
Official website: medios.group